Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients

Table 1

COVID-19 patients’ characteristics at the time of administration.

Characteristic	Total () (%)	Hydroxychloroquine () (16.9%)	Hydroxychloroquine and azithromycin () (83.1%)	value
Age, (year)				0.577
Female	85 (49.4)	16 (55.1)	69 (48.2)	0.497
Intensive care at time of testing	17 (9.8)	3 (10.3)	14 (9.7)	0.927
Tisdale score at treatment initiation,				<0.001
Acute heart failure	28 (16.2)	6 (20.6)	22 (15.3)	0.480
Maximum temperature at the time of administration, (°C)				0.192
Baseline laboratory values,
Serum potassium, (mEq/L)				0.062
Serum creatinine, (mg/dL)				0.810
White blood cell count, (cells/μL)				0.627
Absolute lymphocyte count, (count/μL)				0.325
C-reactive protein, (mg/dL)				0.708
Creatine phosphokinase, (IU/L)				0.940
Lactate dehydrogenase, (IU/L)				0.003
Preexisting conditions
Hypertension	53 (30.8)	10 (34.4)	43 (30.1)	0.639
Congestive heart failure	48 (27.9)	4 (13.7)	44 (30.7)	0.063
Coronary artery disease	11 (6.3)	0 (0)	11 (7.6)	0.123
Atrial fibrillation	2 (1.2)	1 (3.4)	1 (0.7)	0.208
Diabetes mellitus	60 (34.8)	7 (24.1)	53 (37.1)	0.183
Chronic obstructive pulmonary disease	4 (2.3)	0 (0)	4 (2.7)	0.362
Malignancy	7 (4.1)	2 (6.8)	5 (3.4)	0.398
Chronic kidney disease	10 (5.8)	1 (3.4)	9 (6.2)	0.550
Medications
Loop diuretics	41 (23.8)	8 (27.5)	33 (23.1)	0.603

Abbreviations: SD: standard deviation.